Aspirin resistance, defined as persisting platelet activation despite therapeutic dosing, may explain a proportion of treatment failures in the secondary prevention of cardiovascular disease.
Aspirin resistance, characterized by persisting platelet activation despite therapeutic dosing, requires standardized definitions and further research to assess its clinical utility in predicting cardiovascular events.
Aspirin is currently the most cost-effective drug for the secondary prevention of cardiovascular disease, but treatment failures are relatively common. Several factors have been linked to these recurrent vascular events in patients prescribed aspirin, including smoking, drug interactions, nonadherence, comorbid conditions, and aspirin resistance. The term aspirin resistance has been used to describe not only an absence of the expected pharmacologic effects of aspirin on platelets but also poor clinical outcomes, such as recurrent vascular events, in patients treated with aspirin. Aspirin resistance is perhaps more precisely understood as the phenomenon of measurable, persisting platelet activation that occurs in patients prescribed a therapeutic dose of aspirin and may underlie an unknown proportion of aspirin treatment failures. Key challenges for future research are to standardize a definition of aspirin resistance and to compare whether different measures of platelet activation, either alone or in combination, independently predict cardiovascular events. These challenges must be met before researchers conduct studies to assess the clinical utility of testing on patient outcomes and cost-effective prescribing.
Sanderson et al. (Tue,) conducted a review in Cardiovascular disease. Aspirin was evaluated. Aspirin resistance, defined as persisting platelet activation despite therapeutic dosing, may explain a proportion of treatment failures in the secondary prevention of cardiovascular disease.